Inventor · disambiguated record
Birgitte Andersen
Also filed as: ANDERSEN BIRGITTE · ANDERSEN BÍRGÍTTE
14 granted patents·10 pending applications·35 citations·filing 2009–2024
90Inventor score
Files withKJAER TANJA MARIA ROSENKILDE7NOVO NORDISK AS6NOVOZYMES AS4DEFENSIN THERAPEUTICS APS2ANDERSEN BIRGITTE1
Top patents by PatentIndex Score
24 records- 0184US8232242B2Treatment of inflammatory bowel diseases with mammal beta defensinsKJAER TANJA MARIA ROSENKILDE·Filed 2009·Granted Jul 31, 2012·6 cites·8 claims
- 0283US9895417B2FGF21 derivatives and uses thereofNOVO NORDISK AS·Filed 2017·Granted Feb 20, 2018·4 cites·14 claims
- 0382US8232248B2Treatment of rheumatoid arthritis with mammal beta defensinsKJAER TANJA MARIA ROSENKILDE·Filed 2009·Granted Jul 31, 2012·6 cites·9 claims
- 0480US9744213B2FGF21 derivatives and uses thereofNOVO NORDISK AS·Filed 2017·Granted Aug 29, 2017·3 cites·20 claims
- 0580US9279010B2Treatment of inflammatory bowel diseases with mammal beta defensinsDEFENSIN THERAPEUTICS APS·Filed 2014·Granted Mar 8, 2016·5 cites·21 claims
- 0679US10124039B2FGF21 derivatives and uses thereofNOVO NORDISK AS·Filed 2017·Granted Nov 13, 2018·3 cites·10 claims
- 0779US8802621B2Treatment of inflammatory bowel diseases with mammal beta defensinsKJAER TANJA MARIA ROSENKILDE·Filed 2011·Granted Aug 12, 2014·4 cites·19 claims
- 0871US10221404B2Method for modifying characteristics of a lipaseNOVOZYMES AS·Filed 2015·Granted Mar 5, 2019·1 cites·10 claims
- 0967US11578329B2Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expressionNOVO NORDISK AS·Filed 2022·Granted Feb 14, 2023·0 cites·30 claims
- 1067US9217021B2Oral treatment of inflammatory bowel diseaseROSENKILDE KJÆR TANJA MARIA·Filed 2012·Granted Dec 22, 2015·1 cites·14 claims
- 1167US2024400635A1Fusion compounds and uses thereofNOVO NORDISK AS·Filed 2024·Application pending·0 cites
- 1266US2023220398A1Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expressionNOVO NORDISK AS·Filed 2023·Application pending·0 cites
- 1365US9480753B2FGF21 derivatives with albumin binder A-B-C-D-E- and their useTAGMOSE TINA MØLLER·Filed 2010·Granted Nov 1, 2016·2 cites·10 claims
- 1463US10851356B2Method for modifying characteristics of a lipaseNOVOZYMES AS·Filed 2019·Granted Dec 1, 2020·0 cites·10 claims
- 1562US12378542B2Solid stabilized laccase compositionsNOVOZYMES AS·Filed 2021·Granted Aug 5, 2025·0 cites·18 claims
- 1654US2012309678A1Treatment of Inflammatory Bowel Diseases With Mammal Beta DefensinsKJAER TANJA MARIA ROSENKILDE·Filed 2012·Application pending·0 cites
- 1753US9833495B2Oral treatment of inflammatory bowel diseaseDEFENSIN THERAPEUTICS APS·Filed 2015·Granted Dec 5, 2017·0 cites·9 claims
- 1851US2012172298A1Glp-1 and fgf21 combinations for treatment of diabetes type 2ANDERSEN BIRGITTE·Filed 2010·Application pending·0 cites
- 1951US2010016232A1Treatment Of Inflammatory Diseases With Mammal Beta DefensinsNOVOZYMES AS·Filed 2009·Application pending·0 cites
- 2050US2013172235A1Oral treatment of inflammatory bowel diseaseKJAER TANJA MARIA ROSENKILDE·Filed 2012·Application pending·0 cites
- 2146US2012309686A1Treatment of Rheumatoid Arthritis With Mammal Beta DefensinsKJAER TANJA MARIA ROSENKILDE·Filed 2012·Application pending·0 cites
- 2240US2013252884A1Fgf21 analogues and derivativesGARIBAY PATRICK WILLIAM·Filed 2011·Application pending·0 cites
- 2338US2013052213A1Novel immunomodulatory peptideKJAER TANJA MARIA ROSENKILDE·Filed 2012·Application pending·0 cites
- 2432US2012035099A1Fgf21 analogues and derivativesGARIBAY WILLIAM PATRICK·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →